Home › Companies › NEVRO CORP. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NEVRO CORP.’s Form 8-K, filed April 2, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of April 2, 2025: 2 items on NEVRO CORP.’s Form 8-K, filed April 2, 2025: 1 approved · 1 not approved.
No notable dissent beyond the items above.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore NEVRO CORP. in the interactive database Compare manager voting policies
These tallies are NEVRO CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Merger Proposal: To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, Inc., a Delaware corporation ("Globus"), Palmer Merg | 28,350,441 | 684,453 | 90,808 | -- | -- | 98% | Approved | — |
| 2. The Merger Compensation Proposal: To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is based on or otherwise relates to the Merger (the "Me | 9,661,595 | 17,932,514 | 1,531,593 | -- | -- | 35% | Not approved | — |
Source: NEVRO CORP., Form 8-K, filed with the SEC on April 2, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
149 asset managers disclosed a vote on at least one NEVRO CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEVRO CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, Inc., a Delaware corporation ("Globus"), Palmer Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of Globus ("Merger Sub"), and Nevro Corp., a Delaware corporation ("Nevro"), pursuant to which Merger Sub will be merged with and into Nevro, with Nevro surviving as a wholly owned subsidiary of Globus (the "Merger");
NEVRO CORP.’s own tally for this item (“1. Proposal No. 1 - The Merger Proposal: To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, Inc., a Dela”): 28,350,441 for, 684,453 against — passed, per its Form 8-K filed April 2, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Merger Proposal was approved by the requisite vote of Nevro's stockholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 46 asset managers below reported 10,080,427 for, 51,570 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,759,644 | 0 | 0 | 0 | For |
| BlackRock | 1,388,132 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 917,871 | 0 | 0 | 0 | For |
| Fidelity | 829,879 | 0 | 0 | 0 | For |
| GDL FUND | 404,178 | 0 | 0 | 0 | For |
| TIAA | 350,810 | 0 | 0 | 0 | For |
| Charles Schwab | 312,297 | 0 | 0 | 0 | For |
| Equitable | 147,784 | 0 | 51,570 | 0 | Mixed |
| Gabelli | 130,000 | 0 | 0 | 0 | For |
| ALTSHARES TRUST | 114,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 110,564 | 0 | 0 | 0 | For |
| Goldman Sachs | 81,963 | 0 | 0 | 0 | For |
| Dimensional | 73,478 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,601 | 0 | 0 | 0 | For |
| American Century | 43,272 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 40,299 | 0 | 0 | 0 | For |
| Northern Trust | 35,390 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,008 | 0 | 0 | 0 | For |
| Nationwide | 26,262 | 0 | 0 | 0 | For |
| Invesco | 23,647 | 0 | 0 | 0 | For |
| Global X | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 21,024 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 20,264 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,112 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,112 | 0 | 0 | 0 | For |
Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).
91% of fund votes cast · no official result
Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF NECESSARY TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES IN PERSON OR BY PROXY TO APPROVE THE PROPOSAL TO ADOPT THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.
The 45 asset managers below reported 9,163,293 for, 917,124 against, 51,570 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,759,644 | 0 | 0 | 0 | For |
| BlackRock | 1,388,132 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 917,871 | 0 | 0 | 0 | For |
| Fidelity | 67,200 | 762,679 | 0 | 0 | Mixed |
| GDL FUND | 404,178 | 0 | 0 | 0 | For |
| TIAA | 350,810 | 0 | 0 | 0 | For |
| Charles Schwab | 312,297 | 0 | 0 | 0 | For |
| Equitable | 147,784 | 0 | 51,570 | 0 | Mixed |
| Gabelli | 130,000 | 0 | 0 | 0 | For |
| ALTSHARES TRUST | 114,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 110,564 | 0 | 0 | Against |
| Goldman Sachs | 81,963 | 0 | 0 | 0 | For |
| Dimensional | 73,478 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,601 | 0 | 0 | 0 | For |
| American Century | 43,272 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 40,299 | 0 | 0 | 0 | For |
| Northern Trust | 35,390 | 0 | 0 | 0 | For |
| Lincoln Financial | 2,108 | 27,900 | 0 | 0 | Mixed |
| Nationwide | 26,262 | 0 | 0 | 0 | For |
| Invesco | 23,647 | 0 | 0 | 0 | For |
| Global X | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 21,024 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 20,264 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,112 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 16,112 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
35% Not approved · of votes cast
Prior year: 95.2% for (May 23, 2024 meeting) ▼ 60.2 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is based on or otherwise relates to the Merger; and
NEVRO CORP.’s own tally for this item (“2. Proposal No. 2 - The Merger Compensation Proposal: To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is based on or ”): 9,661,595 for, 17,932,514 against — failed, per its Form 8-K filed April 2, 2025 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Merger Compensation Proposal did not receive the requisite vote of Nevro's stockholders and was therefore not approved.”
Support: 35% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 4,759,644 | 0 | 0 | Against |
| BlackRock | 0 | 1,388,132 | 0 | 0 | Against |
| MERIDIAN FUND INC | 0 | 917,871 | 0 | 0 | Against |
| Fidelity | 0 | 829,879 | 0 | 0 | Against |
| GDL FUND | 404,178 | 0 | 0 | 0 | For |
| TIAA | 0 | 350,810 | 0 | 0 | Against |
| Charles Schwab | 0 | 312,297 | 0 | 0 | Against |
| Equitable | 80,000 | 119,354 | 0 | 0 | Mixed |
| Gabelli | 130,000 | 0 | 0 | 0 | For |
| ALTSHARES TRUST | 114,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 110,564 | 0 | 0 | Against |
| Goldman Sachs | 0 | 81,963 | 0 | 0 | Against |
| Dimensional | 0 | 73,478 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 60,601 | 0 | 0 | Against |
| American Century | 0 | 43,272 | 0 | 0 | Against |
| Amplify ETF Trust | 0 | 40,299 | 0 | 0 | Against |
| Northern Trust | 0 | 35,390 | 0 | 0 | Against |
| Lincoln Financial | 27,900 | 2,108 | 0 | 0 | Mixed |
| Nationwide | 0 | 26,262 | 0 | 0 | Against |
| Invesco | 23,647 | 0 | 0 | 0 | For |
| Global X | 0 | 21,293 | 0 | 0 | Against |
| Pacific Life | 0 | 21,024 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 20,264 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 18,112 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 16,112 | 0 | 0 | Against |
Fund voting reports, all 45 managers: 811,022 for, 9,320,965 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ArrowMark Colorado Holdings LLC | 0 | 4,147,892 | 0 | 0 | Against |
| Beryl Capital Management LLC | 2,393,053 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 0 | 1,848,100 | 0 | 0 | Against |
| ODDO BHF ASSET MANAGEMENT SAS | 0 | 0 | 1,463,800 | 0 | Abstain |
| BlackRock | 333 | 1,229,465 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 969,864 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 858,241 | 0 | 0 | Against |
| State Street | 716,835 | 7,476 | 0 | 0 | For |
| DE Shaw | 0 | 717,003 | 0 | 0 | Against |
| Gabelli | 607,250 | 0 | 0 | 0 | For |
| GARDNER LEWIS ASSET MANAGEMENT L P | 512,353 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 500,984 | 0 | 0 | 0 | For |
| Goldman Sachs | 424,692 | 42,127 | 0 | 0 | Mixed |
| Nuveen | 0 | 369,554 | 0 | 0 | Against |
| Charles Schwab | 0 | 312,297 | 0 | 0 | Against |
| Northern Trust | 0 | 299,099 | 0 | 0 | Against |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 0 | 277,430 | 0 | 0 | Against |
| T. Rowe Price | 0 | 275,410 | 0 | 0 | Against |
| Renaissance | 0 | 208,760 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 202,608 | 0 | 0 | Against |
| Citadel | 167,420 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 157,567 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 133,919 | 0 | 0 | Against |
| WATER ISLAND CAPITAL LLC | 114,716 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 66,876 | 0 | 0 | Against |
Institutional-manager reports, all 117 managers: 5,637,084 for, 12,622,445 against, 1,463,800 abstained. Showing the 25 largest; every one is in the interactive database (link above).
0.5% of fund votes cast · no official result
The 4 asset managers below reported 224 for, 45,746 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ALGERT GLOBAL LLC | 0 | 28,420 | 0 | 0 | Against |
| JPMorgan | 0 | 17,326 | 0 | 0 | Against |
| Coyle Financial Counsel LLC | 112 | 0 | 0 | 0 | For |
| SIERRA SUMMIT ADVISORS LLC | 112 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,824,467 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.58% |
| 2 | BlackRock | 3.67% |
| 3 | MERIDIAN FUND INC | 2.43% |
| 4 | Fidelity | 2.19% |
| 5 | GDL FUND | 1.07% |
| 6 | TIAA | 0.93% |
| 7 | Charles Schwab | 0.83% |
| 8 | Equitable | 0.53% |
| 9 | Gabelli | 0.34% |
| 10 | ALTSHARES TRUST | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ArrowMark Colorado Holdings LLC | 10.97% |
| 2 | Beryl Capital Management LLC | 6.33% |
| 3 | Rock Springs Capital Management LP | 4.89% |
| 4 | ODDO BHF ASSET MANAGEMENT SAS | 3.87% |
| 5 | BlackRock | 3.25% |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 2.56% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.27% |
| 8 | State Street | 1.91% |
| 9 | DE Shaw | 1.90% |
| 10 | Gabelli | 1.61% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Armistice Capital, LLC | 3,736,000 | 9.88% | Schedule 13G, filed February 14, 2025 |
| BlackRock | 2,930,783 | 7.75% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 2,072,813 | 5.48% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 2,070,027 | 5.47% | Form 13F, quarter ended March 31, 2025 |
| D.E. Shaw | 1,251,830 | 3.31% | Form 13F, quarter ended March 31, 2025 |
| Renaissance Technologies | 1,209,409 | 3.20% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 880,546 | 2.33% | Form 13F, quarter ended March 31, 2025 |
| State Street | 785,402 | 2.08% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 579,455 | 1.53% | Form 13F, quarter ended March 31, 2025 |
| Nuveen | 369,554 | 0.98% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 37,824,467 shares outstanding, as reported by NEVRO CORP. on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At NEVRO CORP.'s shareholder meeting held April 2, 2025, in the 2024-2025 proxy season, 149 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 539 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or… — NEVRO CORP.'s filing reports the proposal as not approved, with 35% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NEVRO CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 2, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEVRO CORP.’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
NEVRO CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Proxy Votes Now, “NEVRO CORP. 2025 Special Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/nevro-corp/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.